Esosinopholic pancreatitis
Reading File
Now let me search the medical library and PubMed simultaneously for eosinophilic pancreatitis.
Finding Sources
Finding Sources
Searching PubMed
eosinophilic pancreatitis
The library has relevant content in Sleisenger & Fordtran's GI textbook and Robbins. Let me search more specifically and read the relevant sections.
Finding Sources
Finding Sources
Searching PubMed
eosinophilic pancreatitis diagnosis treatment
Excellent findings. Now let me read the key textbook sections and get the PubMed abstracts in parallel.
Reading File
Reading File
Reading Article
PMID: 34026218
Reading Article
PMID: 31120859
Let me now read more of the Sleisenger & Fordtran section on eosinophilic gastroenteritis (which covers pancreatic involvement) and look for the specific pancreatic sections.
Reading File
Finding Sources
Reading Article
PMID: 41801837
Now I have enough information from the textbooks and PubMed for a comprehensive answer. Let me also quickly check Goldman-Cecil for any additional information.
Reading File
I now have comprehensive information to write a thorough answer on eosinophilic pancreatitis.
Eosinophilic Pancreatitis (EP)
Definition and Overview
Eosinophilic pancreatitis is an extremely rare form of pancreatitis defined by predominantly eosinophilic infiltration of pancreatic tissue (>10 eosinophils per high-power field on histology), after secondary causes have been excluded. It accounts for less than 1% of all pancreatitis cases and is prone to misdiagnosis as pancreatic cancer or autoimmune pancreatitis due to overlapping clinical and imaging features.
EP exists on a spectrum with broader eosinophilic GI disorders (EGIDs):
- Isolated EP - eosinophilic infiltration limited to the pancreas
- EP associated with eosinophilic gastroenteritis (EGE) - pancreatic involvement as part of diffuse GI eosinophilic infiltration
- EP in hypereosinophilic syndrome (HES) - multi-organ eosinophilic infiltration including pancreas
Etiology and Pathogenesis
EP is believed to be driven by Th2-mediated immune mechanisms, similar to other EGIDs:
- Th2 cytokines (IL-4, IL-5, IL-13, eotaxin) recruit and activate eosinophils in the pancreatic tissue
- IL-5 is the primary cytokine promoting eosinophil proliferation, maturation, and survival
- About 50% of patients have an atopic history (allergic rhinitis, asthma, eczema, food allergy)
- Food antigens may trigger disease in sensitized individuals
- Mast cells play a co-pathogenic role alongside eosinophils
Secondary causes that must be excluded before diagnosing primary EP:
- Parasitic/helminthic infections (Ascaris, toxocara, anisakis)
- Drug hypersensitivity
- Inflammatory bowel disease
- Myeloproliferative disorders / hypereosinophilic syndrome
- IgG4-related disease (autoimmune pancreatitis type 1)
- Polyarteritis nodosa / eosinophilic granulomatosis with polyangiitis (EGPA/Churg-Strauss)
Clinical Features
EP typically presents acutely or as recurrent episodes of pancreatitis:
| Feature | Frequency |
|---|---|
| Abdominal pain (epigastric, may radiate to back) | Most common |
| Nausea and vomiting | Common |
| Peripheral blood eosinophilia | ~70% of cases |
| Elevated serum amylase/lipase | Present |
| Atopic history | ~50% |
| Obstructive jaundice (pancreatic head mass) | Occasional |
| Diarrhea, weight loss (if co-existing EGE) | Variable |
EP can present as:
- Acute recurrent pancreatitis - most common presentation
- Pancreatic mass lesion - mimicking cancer (especially pancreatic head involvement)
- Chronic pancreatitis with ductal changes
A 2026 case report (Li et al., Am J Case Rep 2026) described a 68-year-old man with recurrent severe abdominal pain, found on EUS-FNA to have ~15 eosinophils/HPF in the pancreas, co-existing with subclinical EGE discovered on routine upper endoscopy.
Diagnosis
Diagnosis is challenging and often delayed. The key elements are:
1. Laboratory Findings
- Peripheral eosinophilia (>500 cells/mm³, often markedly elevated)
- Elevated serum amylase and lipase
- Elevated serum IgE in atopic patients
- Serum IgG4 should be checked to exclude IgG4-related pancreatitis (which may coexist)
2. Imaging
- CT/MRI: diffuse or focal pancreatic enlargement, peripancreatic edema, pancreatic duct dilation, rarely a mass lesion
- MRCP: may show ductal abnormalities
- EUS: can detect focal lesions; allows FNA for tissue diagnosis
3. Histopathology (definitive)
-
10 eosinophils/HPF on pancreatic tissue
- Eosinophilic infiltration of acini, ductal epithelium, and interstitium
- Obtained via EUS-guided fine-needle aspiration (EUS-FNA) or surgical biopsy
- Many patients historically underwent surgery to exclude malignancy before EP was recognized
4. Diagnostic Criteria (Sun et al. 2021)
Based on a review of 19 cases, proposed criteria include:
- Recurrent or acute pancreatitis with no other cause
- Peripheral eosinophilia
- Exclusion of secondary causes
- Histological confirmation of eosinophilic infiltration (>10/HPF)
- Response to corticosteroid therapy
Distinguishing EP from Autoimmune Pancreatitis (AIP Type 1)
| Feature | EP | AIP Type 1 (IgG4-related) |
|---|---|---|
| Peripheral eosinophilia | Common | Less common |
| Serum IgG4 | Normal | Elevated |
| Histology | Eosinophilic infiltrate | Lymphoplasmacytic + storiform fibrosis |
| Other EGID | May co-exist | No |
Treatment
EP responds dramatically and rapidly to corticosteroids - this is both therapeutic and diagnostically supportive.
First-line:
- Prednisolone/prednisone 0.5-1 mg/kg/day orally for 2-6 weeks, then taper
- Symptoms typically resolve within days to weeks
- Pancreatic duct dilation and imaging abnormalities resolve with treatment
Adjunct/dietary:
- Elemental diet or elimination diet (especially if food allergens are identified by skin prick testing or specific IgE)
- Allergen avoidance if a specific trigger is identified
Refractory or steroid-dependent disease:
- Azathioprine or 6-mercaptopurine as steroid-sparing agents
- Lirentelimab (anti-Siglec-8 monoclonal antibody, targeting eosinophils and mast cells) is a promising emerging therapy showing efficacy in EGIDs broadly - Goldman-Cecil Medicine, 7th ed.
- Benralizumab (anti-IL-5 receptor alpha) trials are underway for EGIDs including EP
Surgery is generally NOT required but was historically performed due to misdiagnosis as cancer.
Prognosis
- Response to steroids is usually excellent
- Relapses are common when steroids are tapered, necessitating maintenance therapy or steroid-sparing agents
- A 2019 systematic review (Pinte & Baicus, Rom J Intern Med 2019) analyzing 45 patients found that those with co-existing EGE on histology tended to avoid unnecessary surgery, while isolated EP patients frequently underwent pancreatic resection before the diagnosis was established
- Long-term prognosis is generally favorable with appropriate immunosuppression
Key Takeaways
- EP is a rare but important diagnosis to consider in any patient with pancreatitis + peripheral eosinophilia, especially with atopy
- It is frequently misdiagnosed as pancreatic cancer or AIP, leading to unnecessary surgery
- EUS-FNA is the preferred minimally invasive method for histological confirmation
- Corticosteroids are curative in most cases
- Always exclude secondary causes: parasites, drugs, HES, IgG4-related disease, EGPA
Sources:
- Sleisenger and Fordtran's Gastrointestinal and Liver Disease, 11th ed. (Eosinophilic Gastritis, Enteritis, and Gastroenteritis)
- Goldman-Cecil Medicine, International Edition
- Sun Y et al., Gastroenterol Rep 2021 - Review of pathophysiology, diagnosis, and treatment (PMID 34026218)
- Pinte L & Baicus C, Rom J Intern Med 2019 - Systematic review, EP vs EGE-associated pancreatitis (PMID 31120859)
- Li X et al., Am J Case Rep 2026 - Recurrent EP with EGE, 2026 (PMID 41801837)
This is a shared conversation. Sign in to Orris to start your own chat.